Skip to content
Screener

Whitehawk Therapeutics WHWK Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

Revenue-
EPS-$0.34Beat by $0.21
EPS estimate-$0.55

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.27

Financials

Q4 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$24.9M-31.3%
Net income-$23.3M-27.2%
EPS (diluted)-$0.37+45.6%

Balance sheet

See full
Cash & equivalents$37.6M+31.0%
Total equity$136.3M+160%
Total assets$150.8M+114%

Cash flow

See full
Operating cash flow-$17.2M-14.5%
Free cash flow-$17.2M-13.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$114.05M—
P/S16×—

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-21.8%-9.2pp
Current ratio10.3×+6.7×

Segments

By segment

See full
Reportable-—

FAQ

When did Whitehawk Therapeutics report Q4 2025 earnings?
Whitehawk Therapeutics (WHWK) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Whitehawk Therapeutics's Q4 2025 revenue and EPS?
Whitehawk Therapeutics reported revenue of - and eps of $-0.34 for Q4 2025.
Did Whitehawk Therapeutics beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.55 by $0.21.
How did Whitehawk Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $7.2M a year earlier and eps grew 49.3% from $-0.67.
Where can I find Whitehawk Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-103117) and the 10-K periodic report (0001193125-26-104158) directly on SEC EDGAR. The filing index links above go to sec.gov.